Exosomes in osteosarcoma research and preclinical practice.
Exosomes in osteosarcoma research and preclinical practice.
复制标题
外泌体在骨肉瘤研究和临床前实践中的应用。
DOI：
--
复制
发表时间：
2021
影响因子：
2.2
通讯作者：
Xin Su
中科院分区：
文献类型：
--
作者：
Jin-Tao Shi;Ke-Ping Wang;Xiao-Bo Zhang;Jin Qi;Yi-Cun Hu;Hai-Yu Zhou;Rui-Hao Zhang;Kai Zhang;Xin Su
骨肉瘤是一种罕见的软组织恶性肿瘤，具有较高的肺转移率和死亡率。术前化疗、手术切除病变及术后化疗仍是骨肉瘤的主要治疗方法。然而，对于不可切除、原发性转移或复发疾病的患者，预后很差。最近的研究表明，基于外泌体特征的OS靶向治疗非常有吸引力。外泌体是纳米大小的细胞外囊泡（EVs），通过运输生物活性货物分子参与细胞间的通信，引起OS细胞功能的改变，并在OS疾病进展中发挥重要作用。外泌体具有分泌细胞的特性，可运输货物（如microrna），可用于检测疾病的进展，并可作为临床诊断OS的标志物和/或治疗靶点。本文就外泌体在OS发病、侵袭、转移、耐药、诊断和治疗中的作用进行综述。此外，本文阐述了外泌体在临床应用前需要克服的一系列挑战，并根据现有证据对未来的研究方向提出了建议。
Osteosarcoma (OS) is a rare soft-tissue malignant tumor with high lung metastasis and mortality rates. Preoperative chemotherapy, surgical resection of the lesion and postoperative chemotherapy are still the main treatments for osteosarcoma. The prognosis, however, is poor for patients with nonresectable, primary metastatic or relapsed disease. Recent studies have shown that targeted therapy for OS based on the characteristics of exosomes is very attractive. Exosomes are nanosized extracellular vesicles (EVs) that participate in cell-to-cell communication by transporting biologically active cargo molecules, causing changes in OS cell function and playing important roles in OS disease progression. With the characteristics of secretory cells, exosomes transport cargo (e.g., microRNAs) that can be used to detect the progress of a disease and can serve as markers and/or therapeutic targets for clinical diagnosis of OS. In this review, the roles of exosomes in OS pathogenesis, invasion, metastasis, drug resistance, diagnosis and treatment are summarized. In addition, this article elaborates a series of challenges to overcome before exosomes are applied in clinical practice and provides suggestions based on current evidence for the direction of future research.
登录
查看更多内容
影响因子：
9.7
作者：
Munagala R;Aqil F;Jeyabalan J;Gupta RC
通讯作者：
Gupta RC
影响因子：
4
作者：
Jerez, Sofia;Araya, Hector;Galindo, Mario
通讯作者：
Galindo, Mario
影响因子：
3.1
作者：
Neerukonda, Sabari Nath;Egan, Nicholas A.;Parcells, Mark S.
通讯作者：
Parcells, Mark S.
影响因子：
11.2
作者：
Ashiru O;Boutet P;Fernández-Messina L;Agüera-González S;Skepper JN;Valés-Gómez M;Reyburn HT
通讯作者：
Reyburn HT
DOI：
10.1200/jco.2014.60.0734
发表时间：
2015-07-10
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Bielack SS;Smeland S;Whelan JS;Marina N;Jovic G;Hook JM;Krailo MD;Gebhardt M;Pápai Z;Meyer J;Nadel H;Randall RL;Deffenbaugh C;Nagarajan R;Brennan B;Letson GD;Teot LA;Goorin A;Baumhoer D;Kager L;Werner M;Lau CC;Sundby Hall K;Gelderblom H;Meyers P;Gorlick R;Windhager R;Helmke K;Eriksson M;Hoogerbrugge PM;Schomberg P;Tunn PU;Kühne T;Jürgens H;van den Berg H;Böhling T;Picton S;Renard M;Reichardt P;Gerss J;Butterfass-Bahloul T;Morris C;Hogendoorn PC;Seddon B;Calaminus G;Michelagnoli M;Dhooge C;Sydes MR;Bernstein M;EURAMOS-1 investigators
通讯作者：
EURAMOS-1 investigators